PharmaShots | Incisive News in 3 Shots

Subscribe Now

indivior

PharmaShots Weekly Snapshots (October 09–13, 2023) _

PharmaShots Weekly Snapshots (October 09–13, 2023) _

October 14, 2023

Indivior Entered into an Exclusive License Agreement with Alar to Develop and Commercialise ALA-1000 and Future Buprenorphine-Based LAI Product Candidates

Indivior Entered into an Exclusive License Agreement with Alar to Develop and Commercialise ALA-1000 and Future Buprenorphine-Base...

October 13, 2023

Indivior’s Opvee (nalmefene) Nasal Spray Receives the US FDA’s Approval for Treatment of Opioid Overdose

Indivior’s Opvee (nalmefene) Nasal Spray Receives the US FDA’s Approval for Treatment of Opioid Overdose

May 22, 2023

Indivior to Acquire Opiant Pharmaceuticals for ~$145M

Indivior to Acquire Opiant Pharmaceuticals for ~$145M

November 14, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us